FDA label
What is Lenvima used for?
Lenvima contains lenvatinib. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Lenvima lists 4 uses: Differentiated Thyroid Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma; Endometrial Carcinoma.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Lenvima?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Lenvima, capsule
Indications and Usage, quoted from the label by Eisai Inc. (NDA206947). Cross-references to other label sections are left out.
Differentiated Thyroid Cancer
LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
Renal Cell Carcinoma
LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
LENVIMA, in combination with belzutifan, is indicated for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
LENVIMA, in combination with everolimus, is indicated for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy.
Hepatocellular Carcinoma
LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Endometrial Carcinoma
LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Source: DailyMed label, set id f4bedd21-efde-44c6-9d9c-b48b78d7ed1e, version 82, effective October 14, 2026. NDC 62856-704, one of 5 listings for this product.
Questions
What is Lenvima used for?
The FDA label for Lenvima lists 4 uses: Differentiated Thyroid Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma; Endometrial Carcinoma.
What drug class is Lenvima?
FDA lists lenvatinib in the Kinase Inhibitor established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.